vs
PUMA BIOTECHNOLOGY, INC.（PBYI）与Viridian Therapeutics, Inc.\DE（VRDN）财务数据对比。点击上方公司名可切换其他公司
PUMA BIOTECHNOLOGY, INC.的季度营收约是Viridian Therapeutics, Inc.\DE的1.1倍（$75.5M vs $70.6M），Viridian Therapeutics, Inc.\DE同比增速更快（81958.1% vs 27.7%），PUMA BIOTECHNOLOGY, INC.自由现金流更多（$14.4M vs $-84.7M）
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
Viridian Therapeutics是一家临床阶段生物技术企业，专注于为罕见重症自身免疫及炎症性疾病患者开发新型疾病修饰疗法，核心管线候选产品针对甲状腺眼病，主要业务及市场覆盖北美与欧洲地区。
PBYI vs VRDN — 直观对比
营收规模更大
PBYI
是对方的1.1倍
$70.6M
营收增速更快
VRDN
高出81930.4%
27.7%
自由现金流更多
PBYI
多$99.1M
$-84.7M
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $75.5M | $70.6M |
| 净利润 | — | $-34.6M |
| 毛利率 | 69.3% | — |
| 营业利润率 | 22.7% | -56.7% |
| 净利率 | — | -49.0% |
| 营收同比 | 27.7% | 81958.1% |
| 净利润同比 | — | 54.9% |
| 每股收益（稀释后） | $0.26 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PBYIVRDN
| Q4 25 | $75.5M | — | ||
| Q3 25 | $54.5M | $70.6M | ||
| Q2 25 | $52.4M | — | ||
| Q1 25 | $46.0M | — | ||
| Q4 24 | $59.1M | — | ||
| Q3 24 | $80.5M | — | ||
| Q2 24 | $47.1M | — | ||
| Q1 24 | $43.8M | — |
净利润PBYIVRDN
| Q4 25 | — | — | ||
| Q3 25 | $8.8M | $-34.6M | ||
| Q2 25 | $5.9M | — | ||
| Q1 25 | $3.0M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $20.3M | — | ||
| Q2 24 | $-4.5M | — | ||
| Q1 24 | $-4.8M | — |
毛利率PBYIVRDN
| Q4 25 | 69.3% | — | ||
| Q3 25 | 77.7% | — | ||
| Q2 25 | 76.5% | — | ||
| Q1 25 | 77.1% | — | ||
| Q4 24 | 76.4% | — | ||
| Q3 24 | 63.9% | — | ||
| Q2 24 | 77.4% | — | ||
| Q1 24 | 75.5% | — |
营业利润率PBYIVRDN
| Q4 25 | 22.7% | — | ||
| Q3 25 | 17.6% | -56.7% | ||
| Q2 25 | 12.7% | — | ||
| Q1 25 | 8.7% | — | ||
| Q4 24 | 22.6% | — | ||
| Q3 24 | 27.4% | — | ||
| Q2 24 | -4.6% | — | ||
| Q1 24 | -5.3% | — |
净利率PBYIVRDN
| Q4 25 | — | — | ||
| Q3 25 | 16.2% | -49.0% | ||
| Q2 25 | 11.2% | — | ||
| Q1 25 | 6.5% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 25.2% | — | ||
| Q2 24 | -9.6% | — | ||
| Q1 24 | -11.0% | — |
每股收益（稀释后）PBYIVRDN
| Q4 25 | $0.26 | — | ||
| Q3 25 | $0.17 | — | ||
| Q2 25 | $0.12 | — | ||
| Q1 25 | $0.06 | — | ||
| Q4 24 | $0.40 | — | ||
| Q3 24 | $0.41 | — | ||
| Q2 24 | $-0.09 | — | ||
| Q1 24 | $-0.10 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $97.5M | $490.9M |
| 总债务越低越好 | $22.7M | — |
| 股东权益账面价值 | $130.3M | $503.0M |
| 总资产 | $216.3M | $577.1M |
| 负债/权益比越低杠杆越低 | 0.17× | — |
8季度趋势，按日历期对齐
现金及短期投资PBYIVRDN
| Q4 25 | $97.5M | — | ||
| Q3 25 | $94.4M | $490.9M | ||
| Q2 25 | $96.0M | — | ||
| Q1 25 | $93.2M | — | ||
| Q4 24 | $101.0M | — | ||
| Q3 24 | $96.7M | — | ||
| Q2 24 | $96.8M | — | ||
| Q1 24 | $107.2M | — |
总债务PBYIVRDN
| Q4 25 | $22.7M | — | ||
| Q3 25 | $34.0M | — | ||
| Q2 25 | $45.3M | — | ||
| Q1 25 | $56.7M | — | ||
| Q4 24 | $68.0M | — | ||
| Q3 24 | $79.3M | — | ||
| Q2 24 | $90.7M | — | ||
| Q1 24 | $102.0M | — |
股东权益PBYIVRDN
| Q4 25 | $130.3M | — | ||
| Q3 25 | $115.3M | $503.0M | ||
| Q2 25 | $104.7M | — | ||
| Q1 25 | $97.1M | — | ||
| Q4 24 | $92.1M | — | ||
| Q3 24 | $71.1M | — | ||
| Q2 24 | $48.5M | — | ||
| Q1 24 | $51.0M | — |
总资产PBYIVRDN
| Q4 25 | $216.3M | — | ||
| Q3 25 | $202.9M | $577.1M | ||
| Q2 25 | $194.9M | — | ||
| Q1 25 | $196.2M | — | ||
| Q4 24 | $213.3M | — | ||
| Q3 24 | $220.7M | — | ||
| Q2 24 | $205.0M | — | ||
| Q1 24 | $214.1M | — |
负债/权益比PBYIVRDN
| Q4 25 | 0.17× | — | ||
| Q3 25 | 0.30× | — | ||
| Q2 25 | 0.43× | — | ||
| Q1 25 | 0.58× | — | ||
| Q4 24 | 0.74× | — | ||
| Q3 24 | 1.12× | — | ||
| Q2 24 | 1.87× | — | ||
| Q1 24 | 2.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $14.4M | $-84.6M |
| 自由现金流经营现金流 - 资本支出 | $14.4M | $-84.7M |
| 自由现金流率自由现金流/营收 | 19.1% | -120.1% |
| 资本支出强度资本支出/营收 | 0.0% | 0.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $41.7M | — |
8季度趋势，按日历期对齐
经营现金流PBYIVRDN
| Q4 25 | $14.4M | — | ||
| Q3 25 | $9.7M | $-84.6M | ||
| Q2 25 | $14.1M | — | ||
| Q1 25 | $3.6M | — | ||
| Q4 24 | $15.6M | — | ||
| Q3 24 | $11.0M | — | ||
| Q2 24 | $1.0M | — | ||
| Q1 24 | $11.2M | — |
自由现金流PBYIVRDN
| Q4 25 | $14.4M | — | ||
| Q3 25 | $9.7M | $-84.7M | ||
| Q2 25 | $14.1M | — | ||
| Q1 25 | $3.6M | — | ||
| Q4 24 | $15.6M | — | ||
| Q3 24 | $11.0M | — | ||
| Q2 24 | $1.0M | — | ||
| Q1 24 | — | — |
自由现金流率PBYIVRDN
| Q4 25 | 19.1% | — | ||
| Q3 25 | 17.7% | -120.1% | ||
| Q2 25 | 26.8% | — | ||
| Q1 25 | 7.7% | — | ||
| Q4 24 | 26.4% | — | ||
| Q3 24 | 13.7% | — | ||
| Q2 24 | 2.1% | — | ||
| Q1 24 | — | — |
资本支出强度PBYIVRDN
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | 0.2% | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.0% | — |
现金转化率PBYIVRDN
| Q4 25 | — | — | ||
| Q3 25 | 1.10× | — | ||
| Q2 25 | 2.41× | — | ||
| Q1 25 | 1.21× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.54× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
